17 янв. 2023 г. · 2023 Release Dates. A total of eight FDA-approved adalimumab biosimilars are now cleared for a 2023 release in the United States. For some of ...

13 мар. 2023 г. · The top 10 drugs losing US exclusivity in 2023 · Humira (adalimumab) · Stelara (ustekinumab) · Vyvanse (lisdexamfetamine) · Aubagio (teriflunomide). Humira (adalimumab) · Actemra (tocilizumab)

12 мая 2023 г. · Humira's 20-year exclusivity period ends this year, and its biosimilars are already hitting the U.S. market— beginning with Amgen's Amjevita.

18 июн. 2021 г. · Patients will be able to access lower-cost biosimilar versions of Humira in 2023, approximately 14 years before some of the patents on Humira expire.

28 янв. 2023 г. · For example, an early Humira patent, which expired in 2016, claimed that the drug could treat a condition known as ankylosing spondylitis, a ...

16 дек. 2022 г. · Humira's patent expiration is expected to have a major impact on the pharmaceutical market ... Main patent expiring: 2023. Revlimid, Bristol ...

19 февр. 2021 г. · While Humira's primary patent was set to expire in 2018, it now expires in 2034. An early entry in 2023 would be open to only those biosimilar ...

17 мар. 2022 г. · The entry of Humira biosimilars will be gradual in 2023, with just one from Amgen on the market until mid-year, when five more will launch. This ...

The reason for the delay to 2023 in the US is largely due to a whole host of patents on Humira. While the composition of matter patent covering Humira expired ...